Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2023; 29(4): 706-730
Published online Jan 28, 2023. doi: 10.3748/wjg.v29.i4.706
Published online Jan 28, 2023. doi: 10.3748/wjg.v29.i4.706
Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers
Hai-Ning Liu, Xiao-Fan Wang, Ning-Ping Zhang, Yan-Jie Chen, Xi-Zhong Shen, Hao Wu, Tao-Tao Liu, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Can Yao, Department of Gastroenterology and Hepatology, Minhang District Central Hospital, Fudan University, Shanghai 201199, China
Dong Pan, Department of Internet Technology Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Guo-Ping Zhao, Chinese National Human Genome Center at Shanghai, Zhujiang Hospital, Central Lab, Institute of Plant Physiology and Ecology, Shanghai Institute for Biological Sciences, Shanghai 200032, China
Author contributions: Liu HN, Yao C, and Wang XF contributed equally to this work; Liu HN, Wu H, and Liu TT conceived and designed the experiments; Liu HN, Yao C, and Wang XF drafted the manuscript; Liu HN, Yao C, Wang XF, and Pan D extracted the data; Liu HN, Zhang NP, and Chen YJ performed the statistical analyses; Zhao GP and Shen XZ revised the article; all authors finished reading and approving the final manuscript of this study.
Institutional review board statement: The study was reviewed and approved by the Zhongshan Hospital of Fudan University Institutional Review Board (Approval No. B2018-234).
Informed consent statement: The informed consent was waived from the patients.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at liu.taotao@zs-hospital.sh.cn. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao-Tao Liu, MD, Doctor, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. liu.taotao@zs-hospital.sh.cn
Received: September 18, 2022
Peer-review started: September 18, 2022
First decision: November 15, 2022
Revised: November 28, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 28, 2023
Processing time: 124 Days and 4.2 Hours
Peer-review started: September 18, 2022
First decision: November 15, 2022
Revised: November 28, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 28, 2023
Processing time: 124 Days and 4.2 Hours
Core Tip
Core Tip: This is a retrospective study to reassess the diagnostic and economic value of traditional tumor biomarkers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA72-4 for gastrointestinal malignant tumors in a large sample with novel indicators. Instead of increasing the diagnostic value, CA72-4 should be removed from the list of the health checkup items to avoid the waste of social medical resources for CEA were superior to those of CA19-9, CA72-4 or any other combinations in which it could be applied for early colorectal cancer and a health checkup of CEA for people above 65 years old was economically valuable.